AbbVie Inc's Fiscal Year is From January To December.
The item "Debt-To-Equity-Ratio" stands at -26.02 as of 09/30/2025.
As of the end of AbbVie Inc's third quarter, the item "Debt To Equity Ratio" stands at -26.02. This represents an increase of 93.24 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -37.80 compared to the value the year prior.
The Serie's long term average value is -18.17. It's latest available value, on 09/30/2025, is -7.85 lower, compared to it's long term average value.
The Serie's change from it's minimum value, on 06/30/2025, to it's latest available value, on 09/30/2025, is +359.12 .
The Serie's change from it's maximum value, on 03/31/2025, to it's latest available value, on 09/30/2025, is -75.24 .
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Debt To Equity Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Debt To Equity Ratio | 486,508,953,600.00 |
![]() | Roche Holding AG - Debt To Equity Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Debt To Equity Ratio | 280,205,508,085.11 |
![]() | Novartis AG - Debt To Equity Ratio | 255,096,620,580.91 |